Dripgym Mobile Parent, LLC dba Amp Health

Warning LetterOpen

United StatesIssued Feb 20, 2026Center for Drug Evaluation and Research (CDER)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations2

Issue DateFeb 20, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Dripgym Mobile Parent, LLC dba Amp Health
Location: United States
FEI Number: N/A
Country: United States
Issue Date: February 20, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Summary

Dripgym Mobile Parent, LLC dba Amp Health was warned for making false or misleading claims about compounded semaglutide and tirzepatide products sold through their website. The company misrepresented itself as the compounder of these drugs when it was not, and falsely implied FDA approval by claiming the products contained "the same active ingredient" as FDA-approved drugs like Wegovy, Ozempic, Mounjaro, and Zepbound, despite compounded drugs not being FDA-approved. These violations of sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act resulted in misbranded drugs being introduced into interstate commerce.

Dripgym Mobile Parent, LLC dba Amp Health FDA Warning Letter, February 20, 2026